
    
      This is a prospective, interventional, randomised, open-label, parallel group study
      evaluating the clinical response as well as the dynamics of postprandial chylomicron
      metabolism in patients treated with alipogene tiparvovec with and without immunosuppressants.
      The study will be conducted in 12 LPLD patients who will be randomised into the Immuno+
      (cyclosporin and mycophenolate mofetil) or the Immuno- group.
    
  